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Abstract
Recent studies suggest that tumor-infiltrating immune cells can benefit the tumor by producing factors that pro-
mote angiogenesis and suppress immunity. Because the tumor microenvironment is characterized by high aden-
osine levels, we hypothesized that the low-affinity A2B adenosine receptor located on host immune cells may
participate in these effects. In the current study, we tested this hypothesis in a Lewis lung carcinoma isograft
model using A2B receptor knockout (A2BKO) mice. These mice exhibited significantly attenuated tumor growth
and longer survival times after inoculation with Lewis lung carcinoma compared to wild type (WT) controls.
Lewis lung carcinoma tumors in A2BKO mice contained significantly lower levels of vascular endothelial growth
factor (VEGF) compared to tumors growing in WT animals. This difference was due to VEGF production by host
cells, which comprised 30 ± 2% of total tumor cell population. Stimulation of adenosine receptors on WT tumor-
infiltrating CD45+ immune cells increased VEGF production fivefold, an effect not seen in tumor-associated CD45+
immune cells lacking A2B receptors. In contrast, we found no significant difference in VEGF production between
CD45− tumor cells isolated from WT and A2BKO mice. Thus, our data suggest that tumor cells promote their
growth by exploiting A2B adenosine receptor–dependent regulation of VEGF in host immune cells.
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Introduction
Adenosine is an intermediate product in the metabolism of ATP.
The release of adenosine is dependent on the metabolic state of a cell.
An increase in energy consumption or a decrease in oxygen supply
leads to an enhanced production of adenosine. Metabolically active
solid tumors grow rapidly and routinely experience severe hypoxia
and necrosis that cause adenine nucleotide degradation and adenosine
release. Levels of extracellular adenosine are increased in tumor micro-
environments also due to the changes in activities of enzymes involved
in adenosine metabolism [1,2]. Predictably, several studies demon-
strated an increase in adenosine levels in the tumor interstitium reaching
concentrations in the micromolar range [3,4], compared to physiologi-
cal interstitial levels of 30 to 300 nM found in normal tissues [5].
Adenosine has dual functions as a metabolite and as a regulator of
cellular functions. The regulatory functions of adenosine are medi-
ated through cell surface G protein–coupled adenosine receptors.
Four subtypes of adenosine receptors have been cloned and classified
as A1, A2A, A2B, and A3 [5]. Among adenosine receptors, the A2B
subtype has the lowest affinity to adenosine. In contrast to other
adenosine receptor subtypes, A2B receptors are thought to remain
silent under normal physiological conditions when interstitial adeno-
sine levels are low and become active only when adenosine levels rise
to micromolar concentrations [6].
A2B receptors are ubiquitously distributed in normal tissues [7].
They have been pharmacologically characterized in several cancer cell
lines [8–14]. Analysis of gene expression in primary human tumors
uncovered overexpression of A2B adenosine receptors in cancer tis-
sues, suggesting their potential role in cancer biology [15]. We and
others have shown previously that stimulation of A2B receptors in
cancer cell lines up-regulates the production of angiogenic factors,
suggesting that tumor A2B receptors may promote neovascularization
[10,16,17]. Virtually all tumors arise within a permissive environ-
ment associated with the production of factors that induce angio-
genesis and modify immunity [18]. Most tumors have been shown
to contain an immune infiltrate, which was long thought to represent
the host response to the malignancy. However, recent studies suggest
that the immune cells may actually benefit the tumor by producing a
protumor microenvironment [19]. It is possible, therefore, that not
only adenosine receptors located on cancerous cells but also host A2B
adenosine receptors may participate in protecting malignant tissue.
In the current study, we tested this hypothesis in a Lewis lung carci-
noma (LLC) isograft model using wild type (WT) and A2B adenosine




[1,5-c]-pyrimidine (SCH58261) was a gift from Drs. C. Zocchi
and E. Ongini (Schering Plough Research Institute, Milan, Italy).
3-Ethyl-1-propyl-8-{1-[3-(trifluoromethyl)benzyl]-1H -pyrazol-4-yl}-
3,7-dihydro-1H -purine-2,6-dione (CVT-6883) was provided by
CV Therapeutic, Inc. (Palo Alto, CA) under a sponsored research
agreement. Adenosine, 2-p[2-carboxyethyl]phenethylamino-5′-N -
ethylcarboxamidoadenosine (CGS21680), 5′-N -ethylcarboxamido-
adenosine (NECA), and dimethyl sulfoxide (DMSO) were purchased
from Sigma (St. Louis, MO). When used as a solvent, final DMSO
concentrations in all assays did not exceed 0.1%, and the same
DMSO concentrations were used in vehicle controls.
Cells
Lewis lung carcinoma cells (catalog # CRL-1642) were ob-
tained from American Type Culture Collection (Manassas, VA)
and maintained according to cell culture techniques suggested by
the supplier.
Real-time Reverse Transcription–Polymerase Chain Reaction
Real-time reverse transcription–polymerase chain reaction (RT-
PCR) analysis was performed as previously described [20]. Total
RNA was isolated from cells using the RNeasy Mini kit (Qiagen,
Valencia, CA). Real-time RT-PCR was carried out on ABI PRISM
7900HT Sequence Detection System (PE Applied Biosystems, Foster
City, CA). Primer pairs and 6-carboxy-fluorescein–labeled probes for
murine adenosine receptors and β-actin were provided by Applied
Biosystems. Reverse transcription–polymerase chain reactions using
1 μg of DNase-treated total RNA were performed under conditions
recommended by the manufacturer. A standard curve for each am-
plicon was obtained using serial dilutions of total RNA. The re-
sults from triplicate polymerase chain reactions for a given gene at
each time point were used to determine mRNA quantity relative
to the corresponding standard curve. The relative mRNA quantity
for a given gene measured from a single reverse transcription reaction
was divided by the value obtained for β-actin to correct for fluctua-
tions in input RNA levels and varying efficiencies of reverse tran-
scription reactions.
Measurement of cAMP Accumulation
Cyclic AMP accumulation was measured as previously described
[21]. Lewis lung carcinoma cells were grown in 12-well plates to con-
fluency. Cells were then preincubated in Tyrode’s buffer (150 mM
NaCl, 2.7 mM KCl, 0.37 mM NaH2PO4, 1 mM MgSO4, 1 mM
CaCl2, 5 g/L D-glucose, 10 mM HEPES-NaOH, pH 7.4) containing
1 U/ml adenosine deaminase and the cAMP phosphodiesterase inhib-
itor papaverine (1 mM) for 10 minutes at 37°C. Adenosine receptor
agonists, antagonists, or their vehicle (DMSO)were added to cells, and
the incubation was allowed to proceed for 5 minutes at 37°C. The re-
action was stopped by the addition of 1:5 volume of 25% trichloro-
acetic acid. The extracts were washed five times with 10 volumes of
water-saturated ether. Cyclic AMP concentrations were determined
using a cAMP assay kit (GE Healthcare, Little Chalfont, UK).
Mice
All studies were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals as adopted and promulgated by
the US National Institutes of Health. Animal studies were reviewed
and approved by the institutional animal care and use committee
of Vanderbilt University. Seven- to eight-week-old age- and sex-
matched mice were used. A2BKO mice were obtained from Deltagen
(San Mateo, CA), and wild type C57BL/6 mice were purchased from
Harlan World Headquarters (Indianapolis, IN). Genotyping protocols
for A2BKO have been previously described [22]. All of the A2BKO
mice used in these studies were backcrossed to the C57BL/6 genetic
background for 10 generations.
Isograft Tumor Model
Lewis lung carcinoma cells were dislodged from cell culture plates
by repetitive pipetting with sterile PBS and then pelleted by centri-
fugation at 300g for 10 minutes. Cells were resuspended in PBS and
counted using a hemocytometer. Final concentration was adjusted to
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5 × 106 cells/ml, and 100 μl of cell suspension was injected sub-
cutaneously into the right flank using a tuberculin syringe and a
27-gauge needle. Tumor volume was determined by external mea-
surements using equation, V = [L × W 2] × 0.5, where V is volume,
L is length, and W is width according to published methods [23].
Animals were inspected daily; the time was recorded and plotted as
percentage of survival if mice were found dead or moribund and were
euthanized at the discretion of the veterinarian blinded to animal
group assignments. In all events, tumors did not exceed 2 cm in di-
ameter or 10% of animal weight. To determine tumor weight, total
cell number, and a proportion of tumor-infiltrating host immune
cells, mice were killed at time points indicated under the Results
section. To prepare single-cell suspensions, extracted tumors were
chopped into small pieces, incubated in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% FBS, 1500 U/ml collagenase (Sigma),
and 1000 U/ml hyaluronidase (Sigma) for 1 hour at 37°C, and then
passed through a cell strainer. Total cell numbers were counted, and
CD45+ cell populations that represent tumor-infiltrating host im-
mune cells were analyzed by flow cytometry.
Fluorescence-Activated Cell Sorting
After treatment with FcR Blocking Reagent (Miltenyi Biotec
Inc., Auburn, CA), tumor single-cell suspensions (106 cells/ml) were
labeled using fluorescein isothiocyanate (FITC)–conjugated anti-
CD3e (clone 145-2C11), CD11c (clone HL3), Ly-6C/Gr-1 (clone
RB6-8C5), phycoerythrin-conjugated anti-CD11b (clone M1/70),
CD19 (clone 1D3), and peridinin-chlorophyll-protein–conjugated
anti-CD45 (clone 30-F11) for 20 minutes on ice. All antibodies were
obtained from BD Bioscience Pharmingen (San Jose, CA). Data
acquisition was performed on a FACScalibur flow cytometer (BD
Immunocytometry Systems, Franklin Lakes, NJ), and the data were
analyzed with WinList 5.0 software. Nonviable cells were excluded
by using 7-amino actinomycin D. Antigen negativity was defined
as having the same fluorescent intensity as the isotype control.
Magnetic Cell Separation
Tumor-infiltrating host immune cells were magnetically separated
from isograft tumor cells using CD45 magnetic microbeads following
application protocols of the manufacturer (Miltenyi Biotec Inc.). In
brief, after treatment with FcR Blocking Reagent, tumor single- cell
suspensions (107 cells in 90 μl) were incubated with 10 μl of CD45
microbeads at 4°C for 15 minutes. The cells were then washed and
resuspended in dilution buffer for magnetic cell separation. The la-
beled cells were passed through LS+ separation columns that had been
equilibrated with dilution buffer. The CD45-negative cells were
washed off the column three times with 3 ml of dilution buffer. The
retained CD45-positive cells were eluted from the column outside the
magnetic field by pipetting 5 ml of dilution buffer onto the column.
Analysis of Vascular Endothelial Growth Factor (VEGF)
A Release and VEGF Protein Tissue Levels
To determine VEGF release from LLC cells in culture, cells were
grown to confluency in 12-well plates. One hour before the experi-
ment, the growth medium was replaced with DMEM containing 1×
antibiotic-antimycotic mixture (Sigma) and 1 U/ml adenosine deam-
inase. Cells were incubated in the presence or absence of adenosine
agonists and antagonists in the same medium for 6 hours under hu-
midified atmosphere of air/CO2 (19:1) at 37°C. To determine the
effect of exogenously added adenosine on VEGF release, adenosine
deaminase was excluded from the incubation medium in those par-
ticular experiments. Cell culture supernatants were collected for
VEGF assay.
To compare VEGF protein levels in tumors extracted from WTand
A2BKO mice, tumor tissue (30 mg) was homogenized in 300 μl of
RIPA lysis buffer using a pellet mixer (VWR Scientific, Marietta,
GA). Tissue homogenates were incubated at 4°C for 30 minutes and
then centrifuged at 16,000g for 20 minutes. Protein concentrations
were measured using BCA Protein Assay Kit (Pierce, Rockford, IL).
After adjusting protein concentrations to 1 mg/ml, supernatants were
used to assay VEGF concentrations.
To determine VEGF release from tumor cell populations, mag-
netically separated CD45+ and CD45− cells were counted and then
pelleted by centrifugation. CD45+ cells were resuspended at a con-
centration of 5 × 106 cells/ml in RPMI-1640 medium supplemented
with 10% FBS, 1× antibiotic-antimycotic mixture, 1× nonessen-
tial amino acids (Sigma), 50 μM β-mercaptoethanol, and 1 U/ml
adenosine deaminase. CD45− cells were resuspended at the same
concentration in DMEM supplemented with 10% FBS, 1× antibiotic-
antimycotic mixture, and 1 U/ml adenosine deaminase. Cells were
incubated in the presence or absence of 10 μM NECA for 16 hours
under humidified atmosphere of air/CO2 (19:1) at 37°C. Vascular
endothelial growth factor concentrations in supernatants were mea-
sured using an ELISA kit (R&D Systems, Minneapolis, MN).
Tumor Perfusion Assay
Fifteen minutes before euthanasia, mice received intravenous in-
jections of FITC-labeled dextran (MWt 2,000,000; Sigma) for visu-
alization of blood vessels. Tumors were extracted and fixed in 10%
formalin; 7-μm sections were prepared across their middle part. Ad-
jacent sections were either stained with hematoxylin-eosin or left un-
stained for fluorescence microscopy. Fluorescent images were taken
from tumor sections, and the number of tumor blood vessels identi-
fied by dextran-FITC fluorescence was counted using a fluorescent
microscope (Axiophot; Zeiss, Thornwood, NY). Only areas of viable
tumor tissue were imaged; necrotic regions and overlying subdermal
regions were excluded. For each section, four random images were
captured under low magnification (objective, ×10) and analyzed by
an investigator blinded to the origin of tumors. Vessels that were vis-
ibly interconnected were scored only once. The final vascular density
score represents an average of all scored fields.
Statistical Analysis
Data were analyzed using the GraphPad Prism 4.0 software
(GraphPad Software Inc., San Diego, CA) and presented as mean ±
SEM. Comparisons between treatment groups and a control un-
treated group were performed using one-way ANOVA followed by
Dunnett’s posttests. Comparisons between two groups were per-
formed using two-tailed unpaired t tests. Survival curves were com-
pared using Mantel-Haenszel log rank test. A P value < .05 was
considered significant.
Results
Lewis Lung Carcinoma Cells Express Functional Adenosine
A2B Receptors
Real-time RT-PCR showed that LLC cells preferentially express
mRNA encoding A2B receptors (0.204 ± 0.005% of β-actin;
Figure 1A). Very low levels of A2A receptor mRNA were also detected
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(0.004 ± 0.001% of β-actin), whereas transcripts for A1 and A3 re-
ceptors were below detection levels.
A2A and A2B receptors are known to stimulate adenylate cyclase
through coupling to Gs proteins [5]. Therefore, we measured cAMP
accumulation as a way to determine whether expression of mRNA
translates into functional presence of adenosine receptors in LLC
cells. As seen in Figure 1B, the nonselective adenosine receptor ago-
nist NECA stimulated cAMP accumulation 5.9 ± 0.4-fold at a maxi-
mal concentration of 100 μM, whereas the selective A2A agonist
CGS21680 had no significant effect. Furthermore, the selective
A2B antagonist CVT-6883 [24], but not the selective A2A antagonist
SCH58261 [25,26], inhibited NECA-induced cAMP accumulation
(Figure 1C ).
Lewis lung carcinoma cells tonically release VEGF (Figure 1D).
Stimulation of A2B receptors with NECA, but not A2A receptors with
CGS21680, significantly increased VEGF release from 0.81 ± 0.1 to
1.44 ± 0.08 ng/106 cells (P < .01, n = 4, one-way ANOVA with
Dunnett’s posttest; Figure 1D). The nonselective agonists adenosine
and its stable analog NECA both stimulated VEGF production in
a concentration-dependent manner with estimated EC50 values of
4.2 and 1.2 μM, respectively (Figure 1E ), close to their reported af-
finity at A2B receptors [5,6]. In contrast, the selective A2A agonist
CGS21680 at a concentration 50 times exceeding its reported bind-
ing affinity (K i) at A2A receptors [5] had no effect on VEGF release
from LLC cells (Figure 1D). Furthermore, only the selective A2B an-
tagonist CVT-6883, but not the selective A2A antagonist SCH58261,
inhibited NECA-stimulated VEGF secretion (Figure 1F). On the basis
of these data, we concluded that that LLC cells express functional A2B
receptors linked to the up-regulation of VEGF release.
Prolonged Survival and Attenuated Tumor Growth
in A2BKO Mice
To test the hypothesis that host A2B receptors could be exploited
by tumors for their advantage, we examined whether tumor growth
was suppressed in A2BKO mice relative to WT control animals. The
survival of A2BKO mice was significantly prolonged compared with
WT control animals after subcutaneous injection of LLC cells
(Figure 2A). The tumor growth, expressed as either tumor volume
(Figure 2B) or weight (Figure 2C ), was significantly attenuated in
A2BKO compared to WT hosts. Of interest, an increase in tumor
volume was retarded by 3 to 4 days in A2BKO compared to WT
hosts (Figure 2B), whereas a median survival value for A2BKO mice
was 5 days longer compared to WT control animals (Figure 2A). It is
possible that the relationship between tumor size and survival is not
linear; that is, a relatively small reduction in tumor size leads to a
significant survival benefit. Alternatively, it is also possible that in ad-
dition to a reduced tumor size, other factors can also contribute to
the prolonged survival of A2BKO hosts. Taken together, our results
suggest that the engaging of host A2B adenosine receptors can be
beneficial for tumors and detrimental for host survival.
Figure 1. Characterization of adenosine receptors in LLC cell culture. (A) Real-time RT-PCR analysis of mRNA encoding adenosine re-
ceptor subtypes was performed as described under the Materials and Methods section. Values are expressed as mean of two deter-
minations made in triplicate; nd indicates no transcripts detected. (B) Effects of the nonselective adenosine receptor agonist NECA and
the A2A adenosine receptor selective agonist CGS21680 on cAMP accumulation. Values are expressed as mean ± SEM, n = 3. (C)
Effects of the selective A2A antagonist SCH58261 (100 nM) and the selective A2B antagonist CVT-6883 (100 nM) on NECA-induced cAMP
accumulation. Values are expressed as mean ± SEM, n = 3. Asterisks indicate significant difference (*P < .05, unpaired two-tailed
t tests) between NECA-induced cAMP accumulation in the presence of CVT-6883 and vehicle. (D) Effects of 10 μM NECA and 1 μM
CGS21680 on VEGF release. Values are expressed as mean ± SEM, n = 4. Asterisks indicate significant difference (**P < .01, one-way
ANOVA with Dunnett’s posttest) compared to basal. (E) Effects of adenosine and its stable analog NECA on VEGF release. Values are
expressed as mean ± SEM, n = 3. (F) Effects of 100 nM SCH58261 (SCH, SCH + NECA) and 100 nM CVT-6883 (CVT, CVT + NECA) or
their vehicle (Basal, NECA) on VEGF release in the absence (Basal, SCH, CVT) or in the presence of 10 μM NECA (NECA, SCH + NECA,
CVT + NECA). Values are expressed as mean ± SEM, n= 3. Asterisks indicate significant difference (***P< .001, one-way ANOVA with
Bonferroni’s posttest) between NECA-induced VEGF release in the presence of CVT-6883 and vehicle.
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Flow Cytometry Analysis of Tumor-Infiltrating Host
Immune Cells
Total cell numbers in single-cell suspensions obtained from tumors
extracted from WTmice were higher than those in A2BKO mice (Fig-
ure 3A), reflecting the attenuation of tumor growth in animals lacking
A2B receptors. However, flow cytometric analysis of tumor single-
cell suspensions revealed that the proportion of tumor-infiltrating
CD45+ host immune cells (LLC cells are CD45-negative) was simi-
lar in tumors extracted from WT and A2BKO mice on any given
day after LLC inoculation. The percentage of CD45+ cells in the total
tumor cell population obtained from WT and A2BKO mice was
14.4 ± 1.1% and 13.7 ± 1.9%, respectively, on day 7, increasing to
30.8 ± 1% and 28.8 ± 3.9% by day 14, and then slightly decreasing to
23.3 ± 3.1% and 22.8 ± 1.6% by day 21 (Figure 3B).
Because the percentage of CD45+ cells was the highest 14 days after
LLC inoculation, we chose this time point for further characterization
of host tumor–infiltrating immune cell populations (Figure 4). CD45+
cells were gated (Figure 4A) and analyzed for the expression of lymphoid
lineage cell markers CD19 (B lymphocytes) and CD3e (T lymphocytes)
and of myeloid lineage cell markers CD11b, CD11c, and Gr-1. We
found that cells expressing markers of lymphoid lineage represented a
minor population of tumor-infiltrating host immune cells (Figure 4B),
whereas most cells expressed the common myeloid cell marker CD11b
(Figure 4C ). A considerable proportion of CD11b-positive cells ex-
pressed low levels of CD11c (Figure 4C). CD11b-positive cell popula-
tion also included a subset of CD11bhigh/Gr-1high cells (Figure 4D).
The percentage of CD11b+/CD11c− cells in tumor-infiltrating immune
cells from WT and A2BKO mice was 56.3 ± 1% and 46.4 ± 2.7%,
respectively, whereas the percentage of CD11b+/CD11clow cells was
42.3 ± 0.7% and 44 ± 1%, respectively. Greater (about threefold) dif-
ferences between tumor-infiltrating immune cell populations in WT
and A2BKO mice were found for CD3e
+ cells (2.6 ± 0.3% and 8.7 ±
1.4%, respectively; P < .001, n = 5) and CD11bhigh/Gr-1high cells
(19.5 ± 1.4% and 6.7 ± 0.7%, respectively; P < .001, n = 5).
Host A2B Adenosine Receptors Regulate VEGF Tumor
Tissue Levels
Because A2B receptors are known to regulate VEGF production in
many cell types [10,16,21,27], we next examined the potential role
of host A2B receptors in regulating tumor VEGF levels. On day 14
after LLC inoculation, tissue VEGF protein levels were significantly
lower in the tumors extracted from A2BKO mice, compared to
WT animals (75.7 ± 6.7 vs 126.3 ± 6.5 pg/mg, P = .012, n =
3; Figure 5A). It is possible that the lower intratumoral VEGF levels
in A2BKO mice may reflect the smaller size of the tumors, result-
ing in lower degrees of hypoxia and interstitial adenosine concentra-
tions. It is also possible that A2BKO host cells are phenotypically
distinct, with reduced VEGF production in tumor tissues. To assess
the latter possibility, we prepared single-cell suspensions from tumors
extracted from WT and A2BKO mice and magnetically separated
CD45+ cells from CD45− cells. As seen in Figure 5B, CD45+ cells
isolated from tumors grown in WT mice expressed mRNA encod-
ing adenosine receptor subtypes with the rank order of transcript
levels A2B > A2A > A3, whereas CD45
+ cells isolated from tumors
grown in A2BKO mice exhibited similar levels of transcripts for
A2A and A3 subtypes but lacked mRNA encoding A2B receptors,
reflecting the host origin of these cells. In contrast, expression levels
of transcripts for A2B receptors in CD45
− cells isolated from tumors
grown in WT and A2BKO mice were virtually the same, indicating
their common origin primarily from inoculated LLC cells express-
ing A2B receptors (Figure 5B). Incubation of unstimulated tumor-
infiltrating CD45+ cells from a WT host for 16 hours resulted
in accumulation of low levels of VEGF in cell culture medium
(Figure 5C ). Activation of adenosine receptors with 10 μM NECA
in a fivefold increase in VEGF release from 22.7 ± 1.3 to 117.1 ±
5.1 pg/106 cells. Stimulation of VEGF secretion was dramatically
reduced in tumor-infiltrating A2BKO CD45
+ cells, indicating that
secretion in tumor-infiltrating WT CD45+ cells was mediated mainly
through A2B adenosine receptors. In contrast, tumor CD45
− cells
grown in WT and A2BKO mice were characterized by similar basal
and NECA-stimulated VEGF secretion (Figure 5C ). Thus, our data
indicate that the reduction in tumor tissue VEGF levels observed
in A2BKO mice could be accounted for by the loss of A2B receptor–
mediated regulation of VEGF secretion in tumor-infiltrating host
immune cells. Consistent with reduced tumor tissue VEGF levels,
we observed a lower density of FITC-dextran–perfused vessels in
tumors grafted in A2BKO mice when compared with tumors from
WTmice (Figure 6).
Figure 2. Increased host survival and decreased tumor size in mice lacking A2B adenosine receptors. (A) Survival plot of WT and A2BKO
mice after subcutaneous injection of LLC cells in isograft tumor model as described under the Materials and Methods section. Mantel-
Haenszel log rank test revealed significant difference in survival curves between WT and A2BKO mice (P = .02, n = 5), with median
survival values of 35 and 40 days for WT and A2BKO mice, respectively. (B–C) Tumor growth of LLC was significantly attenuated in
A2BKO compared to WT mice. Tumor volume (B) was determined by direct measurement of tumor dimensions using calipers. Tumor
weight (C) was determined by direct weighting of tumors extracted from euthanized animals on days 7 (7d), 14 (14d), and 21 (21d) after
subcutaneous injection of LLC cells. Data are presented as mean ± SEM of five animals in each group. Asterisks indicate significant
difference (*P < .05, **P < .01, unpaired two-tailed t tests) in corresponding values between WT and A2BKO mice.
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Discussion
Due to their high metabolic activity and hypoxic environment,
solid tumors are characterized by increased release of adenosine
[28]. In this study, we used LLC cells that were previously demon-
strated to release high levels of adenosine into the extracellular space
under hypoxic conditions [4]. Extracellular adenosine levels within
tumors have been shown to reach micromolar concentrations [3,4],
suggesting that all adenosine receptor subtypes, including the low-
affinity A2B receptor, can be activated in this pathophysiological
environment [6,29]. We have previously demonstrated in several dif-
ferent cell cultures that up-regulation of angiogenic factors is an im-
portant function of A2B adenosine receptors [10,16,21,27]. Because
A2B receptors are expressed in various cancerous cells [8–14] and
overexpressed in primary tumors [15,30], it is possible that these re-
ceptors could promote tumor angiogenesis by up-regulating VEGF
levels. Indeed, our data show that cultured LLC cells preferentially
express functional A2B adenosine receptors and that their stimulation
with the stable adenosine analog NECA results in up-regulation of
VEGF secretion. These results correlate with our previous finding
that stimulation of A2B receptors in the human glioblastoma cell line
U87MG up-regulates secretion of angiogenic factors [10], suggesting
that A2B receptors expressed on cancerous cells can promote tumor
angiogenesis and hence their growth.
In addition to A2B receptors located on cancerous cells, we now
report that A2B receptors in host tumor–infiltrating cells also up-
regulate tumor VEGF levels. We found that LLC tumors grown in
host animals lacking A2B adenosine receptors contained significantly
lower levels of VEGF and displayed lower intratumor vascular
density compared to tumors grown in WTanimals. This difference in
neovascularization and tumor tissue VEGF levels was due to the A2B
receptor–dependent VEGF production by host tumor–associated cells,
because stimulation of adenosine receptors in WT tumor-infiltrating
CD45+ immune cells with NECA produced a robust fivefold increase
in VEGF production, an effect not seen in tumor-associated CD45+
immune cells lacking A2B adenosine receptors. In contrast, CD45
−
tumor cells were characterized by elevated tonic VEGF release, but
NECA increased VEGF secretion only by 1.6-fold. Furthermore, we
found no significant difference in VEGF production between CD45−
tumor cells isolated from WT and A2BKO mice. Thus, our data sug-
gest that cancerous cells stimulate neovascularization not only by se-
creting VEGF on their own, but also by exploiting A2B adenosine
receptor–dependent regulation of VEGF production by host tumor–
infiltrating immune cells to help promote tumor growth.
Indeed, assessment of several parameters of tumor growth in WT
and A2BKO mice supports this hypothesis. A2BKO mice exhibited
Figure 4. Expression of lymphoid and myeloid cell markers on the
surface of tumor-infiltrating host immune cells. (A) Single-cell sus-
pensions were prepared from tumors extracted from WT and
A2BKO mice on day 14 after inoculation with LLC cells. CD45
+
cells were gated for flow cytometry analysis of host immune cells
infiltrated into tumor tissues. (B) Cytofluorographic dot plots of
lymphoid cell marker CD19 and CD3e expression in CD45+ cell
populations. (C) Cytofluorographic dot plots of myeloid cell marker
CD11b and CD11c expression in CD45+ cell populations. (D) Cyto-
fluorographic dot plots showing percentage of Gr-1highCD11bhigh
cells in CD45+ cell populations. Representative data from flow
cytometry analysis of cells obtained from six WT (left panels)
and five A2BKO animals (right panels) are shown.
Figure 3. LLC tumors in WT and A2BKO mice contain similar pro-
portions of tumor-infiltrating host immune cells. Single-cell sus-
pensions were obtained as described under the Materials and
Methods section from LLC tumors extracted on days 7 (7d),
14 (14d), and 21 (21d) after subcutaneous injection of LLC cells
in WT and A2BKO mice. (A) Total cell numbers were counted using
a hemocytometer. Total cell numbers in tumors extracted on day 7
from A2BKO and WT mice were 0.40 ± 0.06 × 10
6 and 0.47 ±
0.04 × 106 cells, respectively. (B) Percentage of CD45+ cells in
total tumor cell population was determined by flow cytometry as
described under the Materials and Methods section. Data are pre-
sented as mean ± SEM of three animals in each group. Asterisks
indicate significant difference (*P < .05, unpaired two-tailed
t tests) in corresponding values between WT and A2BKO mice.
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significantly attenuated tumor growth and longer survival times com-
pared with WT controls. Despite the significant difference in tumor
size, weight, and total number of tumor cells, the dynamics of tumor
infiltration with immune cells were similar in WT and A2BKO mice
as judged by the percentage of CD45+ cells in total tumor cell popu-
lations. Two weeks after LLC inoculation, host CD45+ cells repre-
sented about a third of total tumor cell populations in both WT and
A2BKO mice. Our data also show that the overwhelming majority of
CD45+ cells (∼90%) also expressed a common myeloid cell marker
CD11b indicating their myeloid lineage. Although tumor-associated
myeloid cells have been previously suggested to be a significant
source of VEGF [31], the novelty of our findings is that stimulation
of A2B adenosine receptors by tumor-produced adenosine plays an
important role in VEGF secretion by these host tumor–infiltrating
cells resulting in enhanced tumor neovascularization and growth.
Although the percentage of host cells infiltrating the tumor and
the time course of this influx was similar between A2BKO and
WT mice, we found important differences in the subpopulations
of CD45+ cells. In particular, we found that the proportion of
CD11bhigh/Gr-1high cells was threefold lower in tumors grown in
A2BKO mice compared to WT control. In contrast, the propor-
tion of cells expressing CD3e chains of T cell receptor was threefold
higher in tumor-infiltrating CD45+ cells isolated from A2BKO mice
compared to WT control. These findings may reflect differences in
antitumor immune responses between A2BKO and WTmice. Recent
evidence suggests that immature myeloid cells accumulating in tu-
mors play an important role in tumor escape from immune surveil-
lance by suppressing T-cell responses. In mice, these myeloid cells are
characterized as CD11b+/Gr-1+ cells [32] that decrease expression
of CD3e chains of T-cell receptor in lymphocytes infiltrating the
LLC tumors [33]. Our observations raise the interesting possibil-
ity that host A2B receptors not only stimulate tumor angiogenesis
but also suppress immune surveillance, thus engaging two distinct
mechanisms to promote tumor survival and growth. These seem-
ingly independent mechanisms could be related. We have previously
Figure 5. Host A2B adenosine receptors regulate VEGF tumor tissue levels. (A) VEGF protein levels in tumors extracted from WT and
A2BKO mice on day 14 after inoculation with LLC cells. Data are presented as mean ± SEM of three animals in each group. Asterisk
indicates significant difference (*P < .05, unpaired two-tailed t test) between WT and A2BKO mice. (B) Real-time RT-PCR analysis of
adenosine receptor subtype expression in CD45+ and CD45− cells magnetically separated from single-cell suspensions obtained from
tumors extracted from WT and A2BKO mice on day 14 after inoculation with LLC cells as described under the Materials and Methods
section. Results are presented as average of triplicate measurements after two independent cell separations. (C) Release of VEGF from
tumor-infiltrating host CD45+ cells and tumor CD45− cells was measured in conditioned medium after incubation of cells in the ab-
sence (Basal) or presence of 10 μM NECA for 16 hours. Data are presented as mean ± SEM of VEGF secretion from cells separately
isolated from six animals in each group. Asterisks indicate significant difference (***P < .001, unpaired two-tailed t test) between WT
and A2BKO mice.
Figure 6. Decreased density of FITC-dextran perfused vessels in
LLC tumors grown in A2BKO mice. Intratumoral blood vessels
were marked in vivo by FITC-dextran on day 14 after subcutaneous
injection of LLC cells in WT and A2BKO mice as described under
the Materials and Methods section. (A) Representative fluores-
cence micrographs of blood vessels in LLC tumors grown in WT
or A2BKO mice. Scale bar, 200 μm. (B) Vessel counts obtained by
morphometric analysis of LLC tumors. Data are expressed as
number of FITC-dextran perfused vessels (n) per mm2 of viable
tumor tissue. Asterisks indicate significant difference (**P < .01,
n = 9, unpaired two-tailed t test) between WT and A2BKO mice.
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demonstrated that VEGF exerts multiple effects on immune cells and
plays a critical role in the aberrant hemopoiesis [34–36]. Of interest,
VEGF strongly inhibited T-cell development and increased the pro-
duction of CD11bhigh/Gr-1high myeloid cells in mice [34,36]. There-
fore, it is possible that the difference in the expression of Gr-1 and
CD3e markers in CD45+ cells isolated from tumors grown in WT
and A2BKO cells is a reflection of different tumor tissue VEGF levels
found in this study. However, we cannot exclude a direct immuno-
suppressive effect of A2B receptors. It has been recently suggested that
intratumoral adenosine protects cancerous tissues by inhibiting in-
coming antitumor T lymphocytes and natural killer cells through
stimulation of A2A and A2B receptors [4,37]. This putative immuno-
suppressive role of A2B receptors was inferred from studies in A1,
A2A, and A3 adenosine receptor knockout mice, but this hypothesis
was not tested directly using A2BKO mice. Assessment of a potential
role of A2B receptors in suppression of host immune surveillance
would provide additional rationale for the development of A2B an-
tagonists as novel antitumor therapeutic adjunct agents.
It should be noted that our studies were designed to selectively
determine the role of A2B receptors in host cells. We also detected
proangiogenic A2B receptors in tumor cells, but we did not assess
their contribution to adenosine-dependent stimulation of tumor
growth. It is possible, therefore, that our tumor size and survival
analysis underestimate the total importance A2B receptor activation
has on tumor growth. Targeting the low-affinity A2B receptor, as op-
posed to other adenosine receptor subtypes, in the development of
antitumor agents is especially appealing because this receptor is likely
activated only in the pathophysiological tumor environment, while
remaining silent in normal tissues [6]. This characteristic would pro-
vide specificity in targeting tumors, while decreasing the likelihood of
side effects.
In summary, our study revealed for the first time that solid tumors
characterized by an elevated adenosine release can exploit adenosine-
dependent regulation of VEGF production by host tumor–associated
immune cells. We found that host A2B adenosine receptors up-regulate
tumor tissue VEGF levels and increase intratumor vascular density in
a mouse LLC isograft model, thus promoting tumor growth and de-
creasing host survival. Although our study focused primarily on A2B
receptor–mediated VEGF regulation, it is likely that other growth fac-
tors and complementary A2B receptor–dependent mechanisms (e.g.,
immunosuppression) may also contribute to tumor growth.
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